Scopolamine, atropine, edaravone and dexmedetomidine (DrugBank: Atropine, Dexmedetomidine, Scopolamine, Edaravone)
12 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 1 |
4 | Primary lateral sclerosis | 0 |
6 | Parkinson disease | 0 |
21 | Mitochondrial disease | 0 |
34 | Neurofibromatosis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
70 | Spinal stenosis | 0 |
113 | Muscular dystrophy | 0 |
212 | Tricuspid atresia | 0 |
215 | Tetralogy of Fallot | 0 |
226 | Interstitial cystitis with Hunners ulcer | 0 |
280 | Huge arteriovenous malformation with cervicofacial or limb lesion | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04391361 (ClinicalTrials.gov) | November 1, 2020 | 13/5/2020 | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;Respiratory Function;Scopolamine | Drug: Scopolamine, atropine, edaravone and dexmedetomidine;Drug: Edaravone | Ruijin Hospital | NULL | Not yet recruiting | 30 Years | 65 Years | All | 30 | Phase 2 | China |